DNB//Back Bay is pleased to sponsor the BIO International Convention, the largest and most comprehensive event for biotechnology, representing the full ecosystem of biotech with 20,000 industry leaders from across the globe.
Read More
With biopharma pouring more money than ever into weight loss medicines, physicians would like to see improved GLP-1 drugs. But the goals of the two parties are not in full alignment, according to a new study from financing partner DNB Markets and strategic advisory firm Back Bay Life Science Advisors.
Read More
This two-day equity conference is by invitation to institutional healthcare specialist and generalist investors, industry experts, corporate development, and healthcare executives. The NAHC includes sector-specific panel discussions with insights from DNB healthcare equity analysts, industry leaders, and investors.
Read MoreThe commercial success of second-generation radiopharmaceuticals in oncology has re-ignited interest in this modality, resulting in a surge of dealmaking and increased venture financing for companies in the field.
Read MoreWhile psychedelic drugs have been historically stigmatized due to their use as recreational drugs, the commercialization of psychedelics and psychedelic-derived compounds for the treatment of psychiatric and neurological disorders has gained significant momentum over the last 5 years. Two events are seen as watershed moments for the surge of interest in psychedelics.
Read More